Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii-Reference-Cited by-同舟云学术

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Published:2022-05-17 Issue:5 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Falcone Marco¹^ORCID,Tiseo Giusy¹,Leonildi Alessandro²,Della Sala Leonardo¹,Vecchione Alessandra²,Barnini Simona²,Farcomeni Alessio³,Menichetti Francesco¹

Affiliation:

1. Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

2. Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

3. Department of Economics and Finance, University of Rome “Tor Vergata,” Rome, Italy

Abstract

Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, but clinical data are limited. This is an observational retrospective study conducted in the University Hospital of Pisa including consecutive patients with CRAB infections (January 2020 to August 2021).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02142-21

Reference38 articles.

1. World Health Organization. 2021. WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

2. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

3. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

4. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

5. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis;BMC Infectious Diseases;2024-09-13

2. Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex;Expert Review of Anti-infective Therapy;2024-09-08

3. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections;JAC-Antimicrobial Resistance;2024-09-03

4. Prognostic Factors That Affect Mortality Patients with Acinetobacter baumannii Bloodstream Infection;Infection and Drug Resistance;2024-09

5. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint;Journal of Global Antimicrobial Resistance;2024-09